A recent analysis by researchers at the Robert Koch Institute (RKI) suggests that COVID-19 vaccination reduces the risk of developing long COVID, with booster shots potentially offering additional protection. The findings, released on January 14, 2026, come as health officials continue to grapple with the long-term health consequences of the pandemic.
The RKI project, titled “Effectiveness of COVID-19 Vaccination against Long COVID: Epidemiology, Mechanisms and Evidence Synthesis” (VELoCO), is investigating the role of vaccination as a preventative measure against long COVID. The study defines long COVID as symptoms persisting more than four weeks after a SARS-CoV-2 infection, and post-COVID as symptoms lasting more than 12 weeks. Common symptoms include memory and concentration problems, fatigue, sleep disturbances, and respiratory issues. More specific conditions linked to long COVID include Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CSF) and Postural Orthostatic Tachycardia Syndrome (POTS).
Researchers estimate that 6-15% of individuals infected with SARS-CoV-2 will develop long COVID, with risk factors including gender, age, and the severity of the initial infection. While men are more likely to experience severe acute COVID-19, women appear to be at higher risk of developing long COVID, potentially due to a more reactive immune system. Children, the RKI notes, are less likely to develop long COVID than adults.
The precise reasons why some individuals develop long COVID while others do not remain unclear. A separate study, published in Schmerzmed in May 2023, indicated that a subsequent SARS-CoV-2 vaccination in individuals already suffering from long COVID was associated with slight, but significant, symptom relief. The French cohort study, involving 910 unvaccinated individuals with long COVID, “emulated” a randomized controlled trial by comparing those who received a vaccine after infection to a similar group who did not. The type of vaccine – mRNA or vector-based – did not appear to influence the outcome.
Data from the German Society for Neurology (DGN) released in January 2025, showed that receiving two vaccinations *before* a COVID-19 infection did not impact the risk of developing long COVID, while two doses prior to infection did reduce the risk.
While the RKI study and others suggest a protective effect of vaccination, the potential for post-vaccination syndromes remains a subject of investigation. A report in the Deutsches Ärzteblatt notes that, in rare cases, long COVID or Multisystem Inflammatory Syndrome can occur even after COVID-19 vaccination, though at a demonstrably lower risk than following a natural infection. The report acknowledges, yet, that the data on these rare occurrences remains limited.
The VELoCO project is scheduled to conclude in February 2025, and further research is expected to refine understanding of the complex relationship between COVID-19 vaccination and the development of long COVID. The RKI has not yet announced plans for a follow-up study.
